SION-676 / Sionna Therap - LARVOL DELTA

Sionna Therapeutics Announces Presentation of Preclinical Data on NBD1 Stabilizers at 46th European Cystic Fibrosis Conference (PRNewswire) - "Sionna Therapeutics...today announced the presentation of preclinical data demonstrating the activity of the company's portfolio of compounds targeting the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The results are being presented at the European Cystic Fibrosis Society (ECFS) 46th European Cystic Fibrosis Conference held June 7-10 in Vienna, Austria....Sionna is currently conducting a Phase 1 clinical trial evaluating its lead NBD1 modulator, SION-638, and has nominated two additional NBD1 modulators, SION-719 and SION-451, entering Investigational New Drug application (IND) enabling studies in the second half of 2023....The company is also advancing the development of compounds targeting complementary mechanisms including SION-109, which targets NBD1's interface with the ICL4 region, and SION-676, which targets the TMD1 of CFTR."

Pipeline update • Preclinical • Cystic Fibrosis • Genetic Disorders